Berkcan AKKAŞ, Ahmet Ender CAYLAN, Murat UÇAR

Çocuklarda priapizme yaklaşım

Priapizm tanım olarak cinsel istek ve uyarıdan bağımsız yaklaşık 4–6 saat süren uzamış ereksiyon halidir. Pediatrik popülasyonda nadir görül- mekle birlikte altta yatan etiyolojik faktör genellikle orak hücre anemisi olup, hiperkoagülopati, ilaçlar, malignite, toksinler ve idiopatik faktör - lerde altta yatan sebep olabilmektedir. İskemik düşük akımlı priapizm çocuklarda görülen en sık priapizm tipidir. Çocukluk çağında priapizmi yönetmek, kanıta dayalı verilerin olmaması nedeniyle halen klinisyenleri zorlamaktadır. Bu derlemede pediatrik popülasyonda priapizm hakkın- da klinik sınıflandırma, etiyoloji, patofizyolojisi ve güncel tedavileri göz- den geçirilerek sunulmaktadır.

Managing priapism in childhood

Priapism is defined as a persistent erection that prolongs for more than 4 to 6 hours regardless of sexual stimulation. It is rare in pediatdrc population and might be frequently due to sickle cell anemia, hematologic disorders, toxins, malignancy and drugs. Ischemic subtype is the most common type in childhood. It is still challenging for clinicians to manage pediatric age patients with priapism in consequence of lack of well established data. In this review, the literature is searched in order to understand and manage properly the clinical classification, etiology, pathology and novel treatment modalities.

PDF

___

1. Tripe J. Clinical contributions from private practice: case of continued priapism. Lancet. 1845;46:8–9. [CrossRef]
2. Donaldson JF, Rees RW, Steinbrecher HA. Priapism in children: a comprehensive review and clinical guideline. J Pediatr Urol. 2014;10:11–24. [CrossRef]
3. Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med. 2012;9:88–103. [CrossRef]
4. Montorsi F, et al. Sexual medicine: sexual dysfunction in men and woman. Proceedings of the 3rd International Consultation on Sexual Medicine. Paris; 2010.
5. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980;140:1434–7. [CrossRef]
6. Chow K, Payne S. The pharmacological management of intermittent priapismic states. BJU Int. 2008;102:1515–21. [CrossRef]
7. Aktoz, T, Tepeler A, Gündoğdu EO, Ozkuvanci U, Müslümanoğlu AY. Priapism in the newborn: management and review of literature. Andrologia. 2011;43:65–7. [CrossRef]
8. Dust N, Daboval T, Guerra L. Evaluation and management of priapism in a newborn: a case report and review of the literature. Paediatr Child Health. 2011;16:e6–8. [CrossRef]
9. Eland I, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57:970–2. [CrossRef]
10. Kulmala RV, Lehtonen TA, Tammela TL. Priapism, its incidence and seasonal distribution in Finland. Scand J Urol Nephrol. 1995;29:93–6. [CrossRef]
11. Adeyoju A, Olujohungbe ABK, Morris J, Yardumian A, Bareford D, Akenova A, et al. Priapism in sickle cell disease: incidence, risk factors and complications -an international multicentre study. BJU Int. 2002;90:898–902. [CrossRef]
12. Mantadakis E, Ewalt DH, Don Cavender J, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95:78–82. [CrossRef]
13. Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7:476–500. [CrossRef]
14. de Jesus LE, Dekermacher S. Priapism in children: review of pathophysiology and treatment. J Pediatr (Rio J). 2009;85:194– 200. [CrossRef]
15. Castagnetti M, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, et al. Conservative management of priapism secondary to leukemia. Pediatr Blood Cancer. 2008;51:420–3. [CrossRef]
16. Shih WV, Wong C. Priapism and hemodialysis: case report and literature review. Clin Nephrol. 2018;90:64. [CrossRef]
17. Sugihara T, Yasunaga H, Horiguchi H, Nishimatsu H, Matsuda S, Homma Y. Incidence and clinical features of priapism in Japan:46 cases from the Japanese diagnosis procedure combination database 2006-2008. Int J Impot Res. 2011;23:76–80. [CrossRef]
18. Brown JA, Nehra A. Erythropoietin-induced recurrent veno occlusive priapism associated with end-stage renal disease. Urology. 1998;52:328–30. [CrossRef]
19. Brönimann S, Thalhammer F, Springer A, Tonnhofer U, Shariat SF, D’Andrea D. Ischemic priapism in a 12 year old patient associated with coronavirus disease 2019 (COVID-19): a case report. Urology. 2022;165:316–8. [CrossRef]
20. Silverman ML, VanDerVeer SJ, Donnelly TJ. Priapism in COVID-19: a thromboembolic complication. Am J Emerg Med. 2021;45:686.e5–686. e6. [CrossRef]
21. Addar A, Fraidi OA, Nazer A, Althonayan N, Ghazwani Y. Priapism for 10 days in a patient with SARS-CoV-2 pneumonia: a case report. J Surg Case Rep. 2021;2021:rjab020. [CrossRef]
22. Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–15. [CrossRef]
23. Muneer A, Ralph D. Guideline of guidelines: priapism. BJU Int. 2017;119:204–8. [CrossRef]
24. Çelebi MY, Böncüoğlu E, Düzgöl M, Uçan AB, Şencan A, Oral A, Akaslan Kara A. Priapism associated with COVID-19: a pediatric case. Turk J Pediatr. 2022;64:1122–4. [CrossRef]
25. Mockford K, Weston M, Subramaniam R. Management of high flow priapism in paediatric patients: a case report and review of the literature. J Pediatr Urol. 2007;3:404–12. [CrossRef]
26. Yuan J, Desouza R, Westney OL, Wang R. Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl. 2008;10:88–101. [CrossRef]
27. Dubey S, Meluskey HL, Ramsey EZ, Walker SH, Patterson K, Hanna BD. Sildenafil use in pediatric pulmonary hypertension (PH): minimal risk, in D33. Pulmonary hypertension treatment. 2011, American Thoracic Society. p. A5899. [CrossRef]
28. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JPW, Lue TF, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170:1318–24. [CrossRef]
29. Maples BL, Hagemann TM. Treatment of priapism in pediatric patients with sickle cell disease. Am J Health Syst Pharm. 2004;61:355–63. [CrossRef]
30. Succu S, Mascia MS, Melis T, Sanna F, Boi A, Melis MR, Argiolas A. Morphine reduces penile erection induced by the cannabinoid receptor antagonist SR 141617A in male rats: role of paraventricular glutamic acid and nitric oxide. Neurosci Lett. 2006;404:1–5. [CrossRef]
31. Kumar R, Shrivastava DN, Seth A. Spontaneous resolution of delayed onset, posttraumatic high-flow priapism. J Postgrad Med. 2006;52:298. https://pubmed.ncbi.nlm.nih.gov/17102552/
32. Resim S, Sahinkanat T, Karabiber H. High flow priapism of unknown etiology in a prepubertal boy. Pediatr Int. 2004;46:492–3. [CrossRef]
33. Sadeghi-Nejad H, Seftel AD. The etiology, diagnosis, and treatment of priapism: review of the American Foundation for Urologic Disease Consensus Panel Report. Curr Urol Rep. 2002;3:492–8. [CrossRef]
34. Cherian J, Rao AR, Thwaini A, Kapasi F, Shergill IS, Samman R. Medical and surgical management of priapism. Postgrad Med J. 2006;82:89–94. [CrossRef]
35. Chung E, McKnight J, Hosken B. Post traumatic prepubertal high flow priapism: a rare occurrence. Pediatr Surg Int. 2008;24:379– 81. [CrossRef]
36. Hatzichristou D, Salpiggidis G, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Saripoulos D. Management strategy for arterial priapism: therapeutic dilemmas. J Urol. 2002;168:2074–7. [CrossRef]
37. Huang, Y-C, Harraz A, Shindel AW, Lue TF. Evaluation and management of priapism: 2009 update. Nat Rev Urol. 2009;6:262– 71. [CrossRef]
38. Martínez MG, Otero GJM, López SV, Santibáñez FJJ, González MJ, Serrano BE. Penile necrosis: experience in the Hospital de Especialidades Centro Médico Nacional Siglo XXI. Boletín Del Colegio Mexicano de Urología. 2005;20:10–4. https://www. medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=4704
39. Molina L, Bejany D, Lynne CM, Politano VA. Diluted epinephrine solution for the treatment of priapism. J Urol. 1989;141:1127–8. [CrossRef]
40. Gbadoe AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child. 2001;85:52– 3. [CrossRef]
41. Steers WD, Selby Jr JB, Use of methylene blue and selective embolization of the pudendal artery for high flow priapism refractory to medical and surgical treatments. J Urol. 1991;146:1361–3. [CrossRef]
42. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med. 2002;113:252. [CrossRef]
43. Zipper R, Younger A, Tipton T, Jackson B, Prasad M, Hayden G, Stec A. Ischemic priapism in pediatric patients: spontaneous detumescence with ketamine sedation. J Pediatr Urol. 2018;14:465–6. [CrossRef]
44. Baruchel S, Rees J, Bernstein ML, Goodyer P. Relief of sickle cell priapism by hydralazine. Report of a case. Am J Pediatr Hematol Oncol. 1993;15:115–6. [CrossRef]
45. Lowe FC, Jarow JP. Oral terbutaline for the treatment of priapism. J Urol. 1995;153:163–4. [CrossRef]
46. Priyadarshi S. Oral terbutaline in the management of pharmacologically induced prolonged erection. Int J Impot Res. 2004;16:424–6. [CrossRef]
47. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis associated priapism in sickle cell disease. Blood. 2005;106:3264–7. [CrossRef]
48. Okpala I. Investigational agents for sickle cell disease. Expert Opin Investig Drugs. 2006;15:833–42. [CrossRef]
49. Saad ST, Lajolo C, Gilli S, JFC Marques Jr, Lima CS, Costa FF, Arruda VR. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77:45–9. [CrossRef]
50. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67:1043–8. [CrossRef]
51. Levine LA, Guss SP. Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol. 1993;150:475–7. [CrossRef]
52. Steinberg J, Eyre RC. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol. 1995;153:152–3. [CrossRef]
53. Barroso U Jr, Marques TC, Novaes HF. Finasteride for recurrent priapism in children and adolescents: a report on 5 cases. Int Braz J Urol. 2012;38:682–6. [CrossRef]
54. Hoeh MP, Levine LA. Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes. J Sex Med. 2014;11:197–204. [CrossRef]